Discovery - University of Dundee - Online Publications

Library & Learning Centre

Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study

Standard

Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. / Kumar, Pradeep; Kennedy, G.; Khan, F.; Pullar, T.; Belch, J. J. F.

In: Scottish Medical Journal, Vol. 57, No. 2, 05.2012, p. 80-83.

Research output: Contribution to journalArticle

Harvard

Kumar, P, Kennedy, G, Khan, F, Pullar, T & Belch, JJF 2012, 'Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study' Scottish Medical Journal, vol 57, no. 2, pp. 80-83.

APA

Kumar, P., Kennedy, G., Khan, F., Pullar, T., & Belch, J. J. F. (2012). Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scottish Medical Journal, 57(2), 80-83doi: 10.1258/smj.2012.012004

Vancouver

Kumar P, Kennedy G, Khan F, Pullar T, Belch JJF. Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scottish Medical Journal. 2012 May;57(2):80-83.

Author

Kumar, Pradeep; Kennedy, G.; Khan, F.; Pullar, T.; Belch, J. J. F. / Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study.

In: Scottish Medical Journal, Vol. 57, No. 2, 05.2012, p. 80-83.

Research output: Contribution to journalArticle

Bibtex - Download

@article{876858a28c204fc9a39bf64e3c497fb0,
title = "Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study",
author = "Pradeep Kumar and G. Kennedy and F. Khan and T. Pullar and Belch, {J. J. F.}",
year = "2012",
volume = "57",
number = "2",
pages = "80--83",
journal = "Scottish Medical Journal",
issn = "0036-9330",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study

A1 - Kumar,Pradeep

A1 - Kennedy,G.

A1 - Khan,F.

A1 - Pullar,T.

A1 - Belch,J. J. F.

AU - Kumar,Pradeep

AU - Kennedy,G.

AU - Khan,F.

AU - Pullar,T.

AU - Belch,J. J. F.

PY - 2012/5

Y1 - 2012/5

N2 - <p>The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Fifty RA patients were randomized in a double-blind placebo-controlled trial to receive either 10 mg of rosuvastatin or placebo as an adjunct to existing disease-modifying antirheumatic therapy. Patients were followed up for a six-month period. Measurements were done at baseline and six months. CRP and IL-6 were measured in the blood. RA disease activity was measured using disease activity score based on 28 joint counts (DAS 28). When analysing from baseline to six months there was no difference between the rosuvastatin and placebo groups in rheumatoid disease activity (-0.01; standard deviation [SD], 1.08; and +0.18; SD, 0.95; respectively; P value 0.509). There was a trend towards improvement in CRP in the rosuvastatin group (-3.23; SD, 18.18) compared with the placebo group (+17.43; SD, 38.03); P value, 0.161. IL-6 showed a trend towards worsening in the rosuvastatin group (+0.15; SD, 1.09) compared with placebo (-0.73; SD, 1.4); P value, 0.054. These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity.</p>

AB - <p>The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Fifty RA patients were randomized in a double-blind placebo-controlled trial to receive either 10 mg of rosuvastatin or placebo as an adjunct to existing disease-modifying antirheumatic therapy. Patients were followed up for a six-month period. Measurements were done at baseline and six months. CRP and IL-6 were measured in the blood. RA disease activity was measured using disease activity score based on 28 joint counts (DAS 28). When analysing from baseline to six months there was no difference between the rosuvastatin and placebo groups in rheumatoid disease activity (-0.01; standard deviation [SD], 1.08; and +0.18; SD, 0.95; respectively; P value 0.509). There was a trend towards improvement in CRP in the rosuvastatin group (-3.23; SD, 18.18) compared with the placebo group (+17.43; SD, 38.03); P value, 0.161. IL-6 showed a trend towards worsening in the rosuvastatin group (+0.15; SD, 1.09) compared with placebo (-0.73; SD, 1.4); P value, 0.054. These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity.</p>

U2 - 10.1258/smj.2012.012004

DO - 10.1258/smj.2012.012004

M1 - Article

JO - Scottish Medical Journal

JF - Scottish Medical Journal

SN - 0036-9330

IS - 2

VL - 57

SP - 80

EP - 83

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy